NMTC

Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Distributions without Repeated Probe Repositioning EDEN PRAIRIE, Minn., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on the surgical diagnosis and treatment of neurological disorders, today announced the publication of initial clinical results evaluating its OneRF® Trigeminal Nerve Ablation System in the peer-reviewed journal Pain Management.

NeuroOne's FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia EDEN PRAIRIE, Minn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today highlighted a feature article published in the New York Post showcasing the successful treatment of a patient* suffering from trigeminal neuralgia, a debilitating neurological condition, using the Company's FDA 510(k)-cleared OneRF® Trigeminal Nerve Ablation System.

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Research

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.

EDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, today announced a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System.

NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript